Q-omics provides the consensus-scored TRAJ60 profile across patient tissues and cancer cell-line models. TRAJ60 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, TRAJ60 is differentially expressed in 1, with the highest sampling consensus in KIRP. Additionally, TRAJ60 RNA expression shows 5,955 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight READ, KIRP, and LSCC as cancer lineages where TRAJ60 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ60 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ60 survival associations across molecular data types. TRAJ60 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ60 RNA expression–survival associations across cancer types. High TRAJ60 expression shows unfavorable associations in READ, COAD, UCEC, LGG and ESCA, but favorable associations in LUAD. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for TRAJ60 RNA expression.
This table summarizes TRAJ60 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ60. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ60 shows lower tumor expression in KIRP. The KIRP box plot shows higher TRAJ60 RNA expression in normal versus tumor tissue (log2 FC = −0.246, t-test p = .039).
This table shows molecular features associated with TRAJ60 in patient tissues and cancer cell lines. In patient samples, TRAJ60 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
